autologous iCasp9-deltaNGFR-CD19CAR-expressing T cells

{
  "id": "MLC-T-ONC-011660",
  "term": "autologous iCasp9-deltaNGFR-CD19CAR-expressing T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that are transduced with a retroviral vector encoding a chimeric antigen receptor (CAR) specific for the CD19 antigen, the suicide gene, inducible human caspase 9 (iCasp9 or iC9), and a truncated low-affinity nerve growth factor receptor (deltaNGFR), with potential immunomodulating and antineoplastic activities. The iCasp9 construct consists of the entire coding sequence for the human FK506-drug binding protein (FKBP12) with an F36V mutation (FKBP12-F36V) that is linked to the gene encoding human caspase 9, which is deleted of its endogenous caspase activation and recruitment domains. Upon intravenous administration, autologous iCasp9-deltaNGFR-CD19CAR-expressing T cells are selectively toxic to CD19-expressing tumor cells. If the administered T-cells lead to unacceptable side effects, the chemical homodimerizer AP1903 can be administered, which binds to the FKBP12-F36V drug binding domain, activates caspase 9, and results in apoptosis of the administered CAR19 T cells. The CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Prior to administration, deltaNGFR, is used to select the CAR19-transduced T cells for further enrichment by flow cytometry using an anti-NGFR antibody.",
  "synonyms": [
    "autologous ICASP9-deltaNGFR-CD19CAR-expressing T lymphocytes",
    "autologous iC9.2A.deltaNGFR.2A.CAR.CD19 T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-icasp9-deltangfr-cd19car-expressing-t-cells/"
}